Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets.

Taylor OG, Brzozowski JS, Skelding KA.

Front Oncol. 2019 Sep 26;9:963. doi: 10.3389/fonc.2019.00963. eCollection 2019. Review.

2.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
3.

Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.

Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C.

Int J Pharm. 2017 Oct 5;531(1):372-388. doi: 10.1016/j.ijpharm.2017.07.056. Epub 2017 Jul 27. Review.

PMID:
28755993
4.

Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.

Liao W, Fan S, Zheng Y, Liao S, Xiong Y, Li Y, Liu J.

Curr Med Chem. 2018 May 13. doi: 10.2174/0929867325666180514113136. [Epub ahead of print]

PMID:
29768997
5.

Glioblastoma multiforme: State of the art and future therapeutics.

Wilson TA, Karajannis MA, Harter DH.

Surg Neurol Int. 2014 May 8;5:64. doi: 10.4103/2152-7806.132138. eCollection 2014. Review.

6.

Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.

Jena L, McErlean E, McCarthy H.

Drug Deliv Transl Res. 2019 Nov 14. doi: 10.1007/s13346-019-00679-2. [Epub ahead of print] Review.

PMID:
31728942
7.

Drug delivery approaches for the treatment of glioblastoma multiforme.

Fakhoury M.

Artif Cells Nanomed Biotechnol. 2016 Sep;44(6):1365-73. doi: 10.3109/21691401.2015.1052467. Epub 2015 Jun 5. Review.

PMID:
26046399
8.

Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.

Kim SS, Harford JB, Pirollo KF, Chang EH.

Biochem Biophys Res Commun. 2015 Dec 18;468(3):485-9. doi: 10.1016/j.bbrc.2015.06.137. Epub 2015 Jun 24. Review.

9.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
10.

Harnessing nanomedicine for therapeutic intervention in glioblastoma.

Gutkin A, Cohen ZR, Peer D.

Expert Opin Drug Deliv. 2016 Nov;13(11):1573-1582. Epub 2016 Jun 27. Review.

PMID:
27292970
11.

The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Paff M, Alexandru-Abrams D, Hsu FP, Bota DA.

Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002. Review.

12.

Targeted Vascular Drug Delivery in Cerebral Cancer.

Humle N, Johnsen KB, Arendt GA, Nielsen RP, Moos T, Thomsen LB.

Curr Pharm Des. 2016;22(35):5487-5504. Review.

PMID:
27464719
13.

Advances in immunotherapy for the treatment of glioblastoma.

Tivnan A, Heilinger T, Lavelle EC, Prehn JH.

J Neurooncol. 2017 Jan;131(1):1-9. doi: 10.1007/s11060-016-2299-2. Epub 2016 Oct 14. Review.

14.

Current Challenges and Opportunities in Treating Glioblastoma.

Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N.

Pharmacol Rev. 2018 Jul;70(3):412-445. doi: 10.1124/pr.117.014944.

15.

Novel delivery methods bypassing the blood-brain and blood-tumor barriers.

Hendricks BK, Cohen-Gadol AA, Miller JC.

Neurosurg Focus. 2015 Mar;38(3):E10. doi: 10.3171/2015.1.FOCUS14767. Review.

PMID:
25727219
16.

Emerging patents in the therapeutic areas of glioma and glioblastoma.

Harris M, Svensson F, Kopanitsa L, Ladds G, Bailey D.

Expert Opin Ther Pat. 2018 Jul;28(7):573-590. doi: 10.1080/13543776.2018.1494155. Epub 2018 Jul 9. Review.

PMID:
29950117
17.

Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.

Swartz AM, Li QJ, Sampson JH.

Immunotherapy. 2014;6(6):679-90. doi: 10.2217/imt.14.21. Review.

18.

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.

Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Review.

19.

Emerging treatment strategies for glioblastoma multiforme.

Carlsson SK, Brothers SP, Wahlestedt C.

EMBO Mol Med. 2014 Nov;6(11):1359-70. doi: 10.15252/emmm.201302627. Review.

20.

The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.

Zhai L, Dey M, Lauing KL, Gritsina G, Kaur R, Lukas RV, Nicholas MK, Rademaker AW, Dostal CR, McCusker RH, Raizer JJ, Parsa AT, Bloch O, Wainwright DA.

J Clin Neurosci. 2015 Dec;22(12):1964-8. doi: 10.1016/j.jocn.2015.06.018. Epub 2015 Aug 14.

Supplemental Content

Support Center